Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Exclusion Criteria

• •Any of the following:
• •* Pregnant women
• •* Nursing women unwilling to stop breast feeding
• •* Men or women of childbearing potential who are unwilling to employ adequate contraception from the time of registration through cycle 6 (or the final vaccine cycle for each patient)
• •Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
• •Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• •Receiving any other investigational agent
• •Other active malignancy =\< 5 years prior to registration; EXCEPTIONS: Non-melanoma skin cancer or carcinoma-in-situ of the cervix; NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment (cytotoxics, monoclonal antibodies, small molecule inhibitors) for this cancer
• •Known history of autoimmune disease
• •Any contraindication to receiving sargramostim (GM-CSF) or cyclophosphamide
• •Uncontrolled acute or chronic medical conditions including, but not limited to the following:
• •* Active infection requiring antibiotics
• •* Congestive heart failure (New York Heart Association class III or IV; moderate to severe objective evidence of cardiovascular disease)
• •* Myocardial infarction or stroke within previous 6 months
• •Use of a systemic steroid =\< 30 days prior to registration
• •Receiving thyroid replacement therapy